Related Experiment Video
Updated: Jul 12, 2025
Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
Published on: September 27, 2024
Galectin-3's Complex Interactions in Pancreatic Ductal Adenocarcinoma: From Cellular Signaling to Therapeutic
Milica Dimitrijevic Stojanovic1,2, Bojan Stojanovic3, Ivan Radosavljevic3
1Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Abstract:
Galectin-3 (Gal-3) plays a multifaceted role in the development, progression, and prognosis of pancreatic ductal adenocarcinoma (PDAC). This review offers a comprehensive examination of its expression in PDAC, its interaction with various immune cells, signaling pathways, effects on apoptosis, and therapeutic resistance. Additionally, the prognostic significance of serum levels of Gal-3 is discussed, providing insights into its potential utilization as a biomarker. Critical analysis is also extended to the inhibitors of Gal-3 and their potential therapeutic applications in PDAC, offering new avenues for targeted treatments. The intricate nature of Gal-3's role in PDAC reveals a complex landscape that demands a nuanced understanding for potential therapeutic interventions and monitoring.
Insights
Galectin-3 (Gal-3) is crucial in pancreatic ductal adenocarcinoma (PDAC) development and prognosis. Understanding Gal-3
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with complex underlying mechanisms.
- Galectin-3 (Gal-3) is increasingly recognized for its involvement in cancer progression.
- A comprehensive understanding of Gal-3's role in PDAC is essential for developing effective therapies.
Purpose of the Study:
- To review the multifaceted role of Galectin-3 (Gal-3) in pancreatic ductal adenocarcinoma (PDAC).
- To examine Gal-3 expression, immune cell interactions, signaling pathways, apoptosis, and therapeutic resistance in PDAC.
- To evaluate the prognostic significance of serum Gal-3 levels and the therapeutic potential of Gal-3 inhibitors.
Main Methods:
- Comprehensive literature review.
- Analysis of existing studies on Galectin-3 expression and function in PDAC.
- Evaluation of data regarding serum Gal-3 levels and therapeutic strategies targeting Gal-3.
Main Results:
- Galectin-3 (Gal-3) exhibits diverse roles in PDAC development, progression, and prognosis.
- Gal-3 influences immune cell interactions, signaling pathways, apoptosis, and resistance to therapy in PDAC.
- Serum Gal-3 levels show prognostic significance, and Gal-3 inhibitors present potential therapeutic avenues.
Conclusions:
- Galectin-3 (Gal-3) is a key player in pancreatic ductal adenocarcinoma (PDAC), impacting multiple aspects of the disease.
- Serum Gal-3 holds promise as a prognostic biomarker for PDAC.
- Targeting Gal-3 offers a potential strategy for novel PDAC therapeutics, necessitating further research.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...